Citigroup upgraded Hims & Hers Health (HIMS.US) to "neutral" and is bullish on the compliance premium under the Novo Nordisk A/S Sponsored ADR Class B agreement.

Citigroup Inc. has upgraded the rating of Hims & Hers Health (HIMS.US) from "sell" to "neutral," while significantly raising the target price from $13.25 to $24a target price that represents approximately 8% upside based on the closing price on March 9. This upgrade is primarily based on a key agreement the company recently reached with Novo Nordisk A/S Sponsored ADR Class B (NVO.US): by selling Novo Nordisk A/S Sponsored ADR Class B's GLP-1 drugs used for weight loss and type 2 diabetes treatment, Hims & Hers Health has significantly reduced various business risks that the market was previously concerned about, including product pipeline singularity, market competition pressure, and compliance uncertainty. In its latest research report, Citigroup Inc. highly praises this collaboration and sees it as a significant turning point in the history of Hims & Hers. The Citigroup analyst points out that by introducing official medications, Hims & Hers has successfully overcome compliance shadows and legal risks that have long plagued its business model. This transition from selling "complex generics" to "official partners" not only greatly enhances the sustainability of its business but also allows it to penetrate deeper into the lucrative weight loss medical market. This positive news triggered a sharp rebound in the secondary market, with Hims & Hers stock price soaring over 35% in the trading session following the announcement and closing up 40.79% at $22.16 on Monday. Market investors widely believe that Novo Nordisk A/S Sponsored ADR Class B's choice to utilize Hims & Hers' strong remote medical channels and brand influence will accelerate the prevalence of its weight loss drug products among consumers, while Hims & Hers has also established its leadership position in the digital healthcare field. Although the specific pricing for selling Wegovy and Ozempic through its channels has not been disclosed, analyst Daniel Grosslight predicts that the monthly average sales price of these two drugs will be about $100 higher than the official NovoCare cash pay price on Novo Nordisk A/S Sponsored ADR Class B's platform. This premium mainly comes from the value-added service package offered by Hims & Herscustomers can receive support from a professional medical team, personalized nutrition plans, and exercise guidance alongside purchasing medication, forming a bundled value of "medicine + services." At the same time, Grosslight warns of potential risks in this collaboration agreement: according to the agreement, Hims & Hers must cease large-scale self-compounding of semaglutide (the core active ingredient of Wegovy and Ozempic). This restriction may significantly impact its revenue structure, leading to a significant decline in the company's operating revenue and adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization).